東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Chronic myeloid leukemia

Hehlmann, Rudiger.

Linked to FindBook

Google Book

Amazon

博客來

Chronic myeloid leukemia

Record Type:	Electronic resources : Monograph/item
Title/Author:	Chronic myeloid leukemia/ edited by Rudiger Hehlmann.
other author:	Hehlmann, Rudiger.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	x, 255 p. :ill., digital ;24 cm.
[NT 15003449]:	Cytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML-treatment -- A review and up-date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP-competitive BCR-ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response-related predictors of survival -- CML- blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon-alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.
Contained By:	Springer eBooks
Subject:	Chronic myeloid leukemia. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-33198-0
ISBN:	9783319331980

Chronic myeloid leukemia
Chronic myeloid leukemia[electronic resource] /edited by Rudiger Hehlmann. - Cham :Springer International Publishing :2016. - x, 255 p. :ill., digital ;24 cm. - Hematologic malignancies,2197-9766. - Hematologic malignancies..

Cytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML-treatment -- A review and up-date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP-competitive BCR-ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response-related predictors of survival -- CML- blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon-alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.

ISBN: 9783319331980

Standard No.: 10.1007/978-3-319-33198-0doiSubjects--Topical Terms:

2210445
Chronic myeloid leukemia.

LC Class. No.: RC643

Dewey Class. No.: 616.99419

Chronic myeloid leukemia
LDR:02975nmm a2200325 a 4500 001 2048096
003 DE-He213
005 20170118115525.0
006 m d
007 cr nn 008maaau
008 170319s2016 gw s 0 eng d
020 $a 9783319331980 $q (electronic bk.)
020 $a 9783319331973 $q (paper)
024 7 $a 10.1007/978-3-319-33198-0 $2 doi
035 $a 978-3-319-33198-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC643
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
082 0 4 $a 616.99419 $2 23
090 $a RC643 $b .C557 2016
245 0 0 $a Chronic myeloid leukemia $h [electronic resource] / $c edited by Rudiger Hehlmann.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a x, 255 p. : $b ill., digital ; $c 24 cm.
490 1 $a Hematologic malignancies, $x 2197-9766
505 0 $a Cytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML-treatment -- A review and up-date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP-competitive BCR-ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response-related predictors of survival -- CML- blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon-alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.
520 $a This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.
650 0 $a Chronic myeloid leukemia. $3 2210445
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Hematology. $3 808260
700 1 $a Hehlmann, Rudiger. $3 2210444
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Hematologic malignancies. $3 1568109
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-33198-0
950 $a Medicine (Springer-11650)